BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• BioNTech SE has received an average rating of "Moderate Buy" from analysts, with 13 out of 17 analysts recommending buying the stock.
• The average 12-month target price for BioNTech shares is $136.58, with various analysts providing differing price targets ranging from $110.00 to $140.00.
• In institutional trading, several significant investments have occurred, including a notable 3,942.1% increase in stake by Franklin Resources Inc. during the fourth quarter.

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seventeen research firms that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $135.9133.

Several brokerages have weighed in on BNTX. Leerink Partners set a $112.00 price target on BioNTech in a research report on Monday, June 2nd. Truist Financial reaffirmed a "buy" rating and issued a $155.00 price objective (up previously from $151.00) on shares of BioNTech in a report on Tuesday, June 3rd. Bank of America increased their target price on shares of BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday. Morgan Stanley upped their price target on BioNTech from $132.00 to $133.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. Finally, The Goldman Sachs Group assumed coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock.

BioNTech Stock Performance

Shares of BNTX traded up $0.23 during trading hours on Monday, reaching $111.30. 1,181,001 shares of the company traded hands, compared to its average volume of 953,518. The stock has a market capitalization of $26.76 billion, a P/E ratio of -69.56 and a beta of 1.23. The company has a quick ratio of 10.02, a current ratio of 10.18 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average price of $108.59 and a 200-day moving average price of $106.20. BioNTech has a 12-month low of $78.39 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.85%. The firm had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same period in the prior year, the company posted ($3.36) earnings per share. The firm's revenue for the quarter was up 102.6% on a year-over-year basis. Equities analysts anticipate that BioNTech will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in the stock. OneDigital Investment Advisors LLC acquired a new stake in shares of BioNTech during the first quarter valued at about $288,000. Raymond James Financial Inc. acquired a new position in BioNTech during the fourth quarter worth $584,000. GAMMA Investing LLC boosted its position in shares of BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after buying an additional 52,711 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of BioNTech in the fourth quarter valued at $238,000. Finally, Allianz Asset Management GmbH boosted its holdings in BioNTech by 44.3% during the 1st quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock valued at $10,989,000 after acquiring an additional 37,075 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.